LYEL
Lyell Immunopharma, Inc. Common StockstockNASDAQ
we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 15.64 | 2026-11-12 | -11.32% | -3.181 |
| 1M | 8.80 | 2026-10-19 | +57.61% | 3.009 |
| 3M | 15.76 | 2026-08-19 | -11.99% | 2.055 |
| 6M | 16.13 | 2026-05-19 | -14.01% | 1.804 |
| 1Y | 17.22 | 2025-11-19 | -19.45% | 1.802 |
| 2Y | 22.20 | 2024-11-19 | -37.52% | — |
| 5Y | 216.20 | 2021-11-19 | -93.58% | 1.620 |
Lyell Immunopharma, Inc. Common Stock (NASDAQ:LYEL) stock price today is $13.87, and today's volume is 116,090. LYEL is up 1.463% today. The 30 day average volume is 227,249. LYEL market cap is $444.06M with 32.02M shares outstanding.